Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tislelizumab versus investigator's choice salvage chemotherapy in relapsed/refractory classical Hodgkin lymphoma
CTR20201517Phase 3Terminated
- Sponsor
- BeOne Medicines
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in classical Hodgkin lymphoma (cHL), sponsored by BeOne Medicines. Started Dec 2020; status: terminated.
02
Drugs
tislelizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20201517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201517.